The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether early intervention of Silmitasertib restrains the progression of CAP by inhibiting the elevated cytokine release associated with SARS-CoV-2 and Influenza viruses.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-B, PI3K-Akt-mTOR, and JAK-STAT. Inhibition of CK2 by Silmitasertib diminishes the secretion of IL-6 and MCP-1 (Rosenberger et al.). Silmitasertib treatment also reduces the expression of TNF- and CCL4 in NiSO4-stimulated MoDCs (Bourayne et al.). 'Senhwa regards this phase II as the proof-of-concept study to demonstrate Silmitasertib can be a therapeutic strategy that are not restricted to only a specific viral infection, but applicable to various viruses,' said
The global market for related therapeutic drugs has exceeded a value of over
Prior to this phase II study, Silmitasertib was investigated in two investigator-initiated trials (IIT) in
Contact:
Tel: +886-2-8911-9856
Fax: +886-2-8911-9956
(C) 2023 Electronic News Publishing, source